COL6A3

Across TCGA pan-cancer cohorts, COL6A3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated COL6A3 data layer compared with 24 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher COL6A3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated COL6A3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where COL6A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.955	0.738	.001	79	view →
LSCC	OS	Median	All	0.920	1.000	.008	18	view →
HNSC	OS	Quartile	III,IV	0.556	0.796	.015	15	view →
PDAC	OS	Tertile	III,IV	0.362	1.000	.022	12	view →
LUAD	OS	Median	All	0.939	0.982	.017	11	view →
GBM	OS	Tertile	All	0.784	0.926	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

COL6A3–CCRCC (OS)

Open the CCRCC breakdown →